<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074435</url>
  </required_header>
  <id_info>
    <org_study_id>InstitutRD</org_study_id>
    <nct_id>NCT03074435</nct_id>
  </id_info>
  <brief_title>Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire</brief_title>
  <acronym>REACT</acronym>
  <official_title>Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherche en Sciences de la Sante, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pierre Richet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefit to use 1) insecticidal paints, 2) larvicides, 3) Ivermectin
      for both human and domestic animals and 4) strengthened Information, Education and
      Communication (IEC) strategy to complement the universal coverage with LLINs through a
      cluster randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insecticidal paint comprised of two organophosphates (OPs) and an Insect Growth Regulator
      (IGR). This tool targets adult mosquitoes that are resistant pyrethroids to reduce vector
      density.

      Larvicide is a new formulation of Bacillus thuringiensis israelensis that will be implemented
      in major permanent breeding sites with the objective to reduce vector density.

      Ivermectin will be injected to domestic animals in addition to the national campaign
      implemented in the study area which treats the whole population. Ivermectin reduces the
      survival of mosquito that blood feed on treated humans and animals.

      Information, Education and Communication strategy aims to increase the adherence of the
      population to control tools available. Strengthening the IEC aims to increase the good use of
      long lasting nets.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malaria incidence</measure>
    <time_frame>continuous monitoring during 2 years</time_frame>
    <description>Malaria cases reported in local health system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Entomological Inoculation Rate</measure>
    <time_frame>Every 8 weeks during 2 years</time_frame>
    <description>Number of infectious bites/personn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria prevalence</measure>
    <time_frame>Every 4 months during 2 years</time_frame>
    <description>% of positive blood smears among the population between 6 months to 20 years</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insecticidal paint</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Larvicides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Information, Education, Communication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insecticidal paint</intervention_name>
    <description>Houses will be painted with insecticidal paint</description>
    <arm_group_label>insecticidal paint</arm_group_label>
    <other_name>Inestfly 5A IGR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Larvicide</intervention_name>
    <description>Larval breeding sites will be treated with larvicide</description>
    <arm_group_label>Larvicides</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Doses of Ivermectin will be injected to peri-domestic animals</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>IEC</intervention_name>
    <description>A reinforced information, education and communication strategy will be implemented.</description>
    <arm_group_label>Information, Education, Communication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be an inhabitant of the villages included into the RCT

          -  Aged from 6month old to 20 years old

        Exclusion Criteria:

          -  older than 20 year old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cédric Pennetier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Rehcerche pour le Développement</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>Cédric PENNETIER</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

